WHO Raises Concern Over Critical Shortage of Obesity Injections

Fewer than a tenth of patients eligible to benefit from GLP-1 drugs like Wegovy are able to get them, states the WHO as it releases its first recommendations on the medications.

With over a billion individuals worldwide now obese, it is calling for increased and just access to GLP-1 medication.

Based on projections, over two billion will be living with obesity by 2030 without intervention.

"Our latest guidance acknowledges that excess weight is a long-term condition that can be treated with comprehensive and lifelong care," remarked WHO director-general Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and distribution challenges are major barriers to universal access to the treatments that can help people shift substantial weight, notes the organization.

Skinny Jab Shortage

Even under the present most optimistic case, the supply of these medications would only suffice for approximately 100 million people – less than 10% of those who need them, according to the health organization.

The recommendation encourages nations and manufacturers to expand availability, via approaches such as licensing agreements.

Exclusive production rights on a key compound – the primary component of the drug Wegovy – is due to expire in several countries in 2026.

How Weight-Loss Injections Operate

These medications mimick a natural hormone to slow digestion, curb appetite and boost satiety so users reduce food intake.

People usually see weight reduction after several weeks of beginning the once-weekly jabs.

Studies indicates patients may regain a significant portion after a year of stopping the medication, as their typical hunger return.

To be above a healthy weight elevates your likelihood for developing health problems, like type 2 diabetes, cardiovascular issues, stroke, and some malignancies.

Obesity affects people in all nations and was linked to 3.7 million fatalities worldwide in 2024, per the WHO.